Envoplakin, IgG Antibody

The intended use of the assay is semiquantitative determination of human IgG antibodies against envoplakin in serum and supports the delimitation of a paraneoplastic pemphigus from bullous pemphigoid, pemphigus vulgaris or pemphigus foliaceus. Paraneoplastic pemphigus (PNP), also referred to as paraneoplastic autoimmune multiorgan syndrome (PAMS), is a rare condition associated with lymphoproliferative disorders and other malignancies. It can occur at any age and typically presents with severe pemphigus like clinical features and a high mortality rate. Patients with PNP/PAMS produce serum antibodies against multiple epithelial types (simple, columnar, transitional), targeting several antigens, with envoplakin being a major one. Measurement of IgG envoplakin antibody levels by ELISA, whether elevated or normal, cannot independently confirm or exclude PNP/PAMS; rather, it serves as a supportive marker when interpreted alongside other diagnostic indicators. Elevated IgG envoplakin levels may correlate with disease severity and activity, making them useful for monitoring disease progression.